Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)

• Company Description    X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $4.04 Daily Weekly Monthly 20 Day Moving Average: 573,653 shares Shares Outstanding: 99.15 (millions) Market Capitalization: $400.55 (millions) Beta: 0.39 52 Week High: $4.83 52 Week Low: $2.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.94% -4.52% 12 Week -0.98% -3.09% Year To Date 1.00% -10.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 61 North Beacon Street 4th Floor - Boston,MA 02134 USA ph: 857-529-8300 fax: - ir@x4pharma.com http://www.x4pharma.com

• General Corporate Information    Officers Adam R. Craig - President and Chief Executive Officer Adam R. Craig - Executive Chairman David Kirske - Chief Financial Officer and Treasurer Michael S. Wyzga - Director Gary J. Bridger - Director Peer Information X4 Pharmaceuticals, Inc. (CORR.) X4 Pharmaceuticals, Inc. (RSPI) X4 Pharmaceuticals, Inc. (CGXP) X4 Pharmaceuticals, Inc. (BGEN) X4 Pharmaceuticals, Inc. (GTBP) X4 Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98420X202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 99.15 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.39 Market Capitalization: $400.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.45 Price/Cash Flow: - Price / Sales: 25.28 EPS Growth vs. Year Ago Period: 96.25% vs. Previous Quarter: 18.75% Sales Growth vs. Year Ago Period: 346.33% vs. Previous Quarter: 225.18% ROE 06/30/26 - -63.05 03/31/26 - -94.90 12/31/25 - -115.27 ROA 06/30/26 - -36.89 03/31/26 - -48.09 12/31/25 - -45.97 Current Ratio 06/30/26 - 11.30 03/31/26 - 10.18 12/31/25 - 10.16 Quick Ratio 06/30/26 - 11.02 03/31/26 - 9.98 12/31/25 - 9.98 Operating Margin 06/30/26 - -568.80 03/31/26 - -1,106.30 12/31/25 - -225.55 Net Margin 06/30/26 - -568.80 03/31/26 - -1,106.30 12/31/25 - -225.55 Pre-Tax Margin 06/30/26 - -568.98 03/31/26 - -1,106.22 12/31/25 - -225.44 Book Value 06/30/26 - 1.65 03/31/26 - 1.79 12/31/25 - 2.13 Inventory Turnover 06/30/26 - 0.63 03/31/26 - 0.40 12/31/25 - 1.55 Debt-to-Equity 06/30/26 - 0.49 03/31/26 - 0.45 12/31/25 - 0.41 Debt-to-Capital 06/30/26 - 33.06 03/31/26 - 31.24 12/31/25 - 29.05

Powered by Zacks Investment Research ©